DAIC

MAY 6, 2024

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Circulation

JANUARY 22, 2025

In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF. Circulation, Ahead of Print.

Preserved Ejection Fraction 55

Preserved Ejection Fraction Outpatient Heart Failure BMI 55

European Journal of Heart Failure

NOVEMBER 29, 2023

Methods Between 1 November 2018 and 31 December 2020, 10 162 patients with chronic or acute/worsening HF with reduced, mildly reduced, or preserved ejection fraction were enrolled from 220 centres in 41 European or ESC affiliated countries.

Heart Failure 75

Heart Failure Preserved Ejection Fraction Quality of Life Biomarkers 75

European Journal of Heart Failure

MARCH 30, 2025

We assessed the associations of MetS indices with echocardiographic parameters, biomarkers of myocardial damage (high-sensitivity cardiac troponin I [hs-cTnI] and B-type natriuretic peptide [BNP]) and incident HF hospitalizations including HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF).

Heart Failure 40

Heart Failure Preserved Ejection Fraction Biomarkers BMI 40

European Journal of Heart Failure

MARCH 4, 2024

CI, confidence interval; CV, cardiovascular; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalization for heart failure. The primary outcome was a composite of first HF hospitalization or cardiovascular (CV) death.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Hospital Biomarkers 40

Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

BackgroundHeart failure with preserved ejection fraction (HFpEF) is a common and heterogeneous syndrome with high mortality and morbidity. The patients were divided into two groups according to the 24-month follow-up results: deceased (82 cases) and survivors (330 cases).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Risk Factors Biomarkers Hospital 52

Frontiers in Cardiovascular Medicine

NOVEMBER 10, 2024

BackgroundHeart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) often coincide. During follow-up, HFpEF-patients more often experienced AF-related re-hospitalization (36.8% Forty-two were female. ml/m2 vs. 25.8 ml/m2, g/m2 vs. 83.0 g/m2, vs. 31.1%, P = 0.109).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 52